Recursion Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Recursion Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 2 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Recursion Pharmaceuticals: 6 sponsored US clinical trials, 2 recruiting.

Recursion Pharmaceuticals sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed/Refractory Lymphomas, with 1 trials.

Upper-quartile sponsor footprint

Recursion Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 1

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

NCT06678659
RECRUITING Phase 1

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

NCT05552755
TERMINATED Phase 2

The Clostridioides Difficile Trial of REC-3964

NCT06536465
TERMINATED Phase 2

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

NCT06005974
TERMINATED Phase 2

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

NCT05130866
COMPLETED Phase 2

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

NCT05085561

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4

Therapeutic Areas

Relapsed/Refractory Lymphomas 1
Metastatic Cancers 1
Locally Advanced 1
Unresectable 1
Familial Adenomatous Polyposis 1

What is open in the Recursion Pharmaceuticals pipeline

2 recruiting of 6 indexed (33% open); 1 completed (17%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Relapsed/Refractory Lymphomas (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Recursion Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Recursion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%20%40%60%80% Total trials Recruiting share Recursion Pharmaceuticals23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Recursion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Recursion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Recursion Pharmaceuticals page

6 registered trials is a research-attention snapshot, not an endorsement of Recursion Pharmaceuticals or any single study.

  • 2 of Recursion Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Relapsed/Refractory Lymphomas is the condition Recursion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed/Refractory Lymphomas trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Recursion Pharmaceuticals pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.